← All Stocks

Pfizer Inc.

PFE · NYQ
$28.18+0.90%
52W Low: $23.5852W High: $29.21
Current: $28.18  ·  82% of 52-week range
HealthcareDrug Manufacturers - GeneralNYQ
View live charts, options flow & technicals for Pfizer Inc. → Open Dashboard

Pfizer Inc. (PFE) is a healthcare company in the drug manufacturers - general industry with $63.70B in trailing revenue trading at a 36.6× trailing P/E — analyst consensus: buy.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Key Statistics

Market Cap$160.62B
Revenue (TTM)$63.70B
EPS (TTM)$0.77
EPS (Fwd est.)$2.90
Employees75,000
Trailing P/E36.60
Forward P/E9.73
PEG Ratio12.78
Price / Sales2.52
Price / Book1.89
EV / EBITDA8.38
Beta (5Y)0.30

Analyst Consensus

Consensus
Buy
Analyst Price Target
+2.5% upside
Target: $28.88

Annual Revenue & Net Income

RevenueNet Income
'22
$101.17B
$31.37B
'23
$59.55B
$2.12B
'24
$63.63B
$8.03B
'25
$62.58B
$7.77B

Earnings History


QuarterActual EPSEstimateResult
Aug 2026
$0.77
$0.68Beat (+12.9%)
May 2026
$0.75
$0.72Beat (+3.9%)
Feb 2026
$0.66
$0.57Beat (+16.2%)
Nov 2025
$0.87
$0.63Beat (+37.4%)

Next Earnings Report

Pfizer Inc. is next expected to report earnings on 03 Nov 2026.

Profitability

74.7%
27.9%
6.8%
Gross
Margin
Operating
Margin
Net
Margin
Revenue Growth (YoY)2.6%
Return on Equity5.0%
Return on Assets5.8%

Balance Sheet

Cash & Equivalents$11.70B
Total Debt$63.48B
Net Position$51.78B (net debt)
Free Cash Flow (TTM)$12.49B
Debt / Equity74.25

Share Ownership

Institutions 69.1%
Insiders 0.1%
Public 30.8%

Dividend

Annual Rate
$1.72
Yield
6.16%
Payout Ratio
226.3%
Ex-Dividend Date
24 Jul 2026
5Y Avg Yield
5.20%

Related Stocks

LLYUNHJNJMRKABBVTMOISRGBMY

Frequently Asked Questions

What does Pfizer Inc. (PFE) do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret br…
What is PFE's market cap?
Pfizer Inc. has a market capitalization of approximately $160.62B.
What is PFE's P/E ratio?
Pfizer Inc. trades at a trailing P/E ratio of 36.6x and a forward P/E of 9.7x, which is above the broad market average of ~25x.
How much revenue does PFE generate?
Pfizer Inc. generated $63.70B in trailing 12-month revenue.
What do analysts say about PFE?
The analyst consensus rating for Pfizer Inc. is buy, with a mean price target of $28.88. That implies +2.5% upside from the current price.
When does PFE report earnings?
Pfizer Inc. is next scheduled to report earnings on 03 Nov 2026.
Does PFE pay a dividend?
Yes. Pfizer Inc. pays a dividend with a current yield of 6.16%, at an annual rate of $1.72 per share.

View live charts, options flow, gamma exposure, earnings history, and technical analysis for Pfizer Inc. on Apsis Markets.

Open Live Dashboard →